🇺🇸 Decitabine/Cedazuridine in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 2 reports (18.18%)
  2. Angioedema — 1 report (9.09%)
  3. Cervical Vertebral Fracture — 1 report (9.09%)
  4. Death — 1 report (9.09%)
  5. Increased Upper Airway Secretion — 1 report (9.09%)
  6. Lumbar Vertebral Fracture — 1 report (9.09%)
  7. Mobility Decreased — 1 report (9.09%)
  8. Plasma Cell Myeloma — 1 report (9.09%)
  9. Red Blood Cell Count Decreased — 1 report (9.09%)
  10. Speech Disorder — 1 report (9.09%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Decitabine/Cedazuridine approved in United States?

Decitabine/Cedazuridine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Decitabine/Cedazuridine in United States?

Astex Pharmaceuticals, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.